NonAlcoholic Steatohepatitis NASH: Dynamic Market Forecast to 2026 [Report Updated: 28092018] Prices from USD $7221

00:20 EST 29 Nov 2018 | BioPortfolio Report Blog

NonAlcoholic Steatohepatitis NASH: Dynamic Market Forecast to 2026


Nonalcoholic steatohepatitis NASH is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of nonalcoholic fatty liver disease NAFLD. NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular cancer.

Therapeutic options for NASH are currently very limited, with Vitamin E being the standard of care for patients. This leaves significant unmet need for the disease and, coupled with high disease prevalence in developed countries, results in enticing opportunities for drug developers. As such, there is a very active pipeline for NASH, and many new products are expected to launch over the next 10 years. However, there is still uncertainty over how the NASH treatment landscape will develop as these new products launch.

Key Questions Answered

The NASH market is poised to undergo rapid expansion during the forecast period and beyond. What are the main drivers of this expansion?

What are the main unmet needs in NASH? Will the drugs under development fulfil these needs?

Which patients are the most likely to receive drug treatment for NASH during the forecast period, and which patients are unlikely to be reimbursed?


Components of the slide deck include

Timeline of marketimpacting events

Key clinical trial landscape updates

Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective

Overview of updates to the forecast model based on anticipated future impact of events

Forwardlooking events calendar listing expected key updates to the NASH competitive space through September 2019

Other events included in the analysis include

Regulatory filings

Approval decisions

Pricing changes

Patent litigation

Clinical trial data announcements

Clinical trial failures

Clinical trial timeline updates.

Reasons to buy

The report will enable you to

Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NASH therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Original Article: NonAlcoholic Steatohepatitis NASH: Dynamic Market Forecast to 2026 [Report Updated: 28092018] Prices from USD $7221


More From BioPortfolio on "NonAlcoholic Steatohepatitis NASH: Dynamic Market Forecast to 2026 [Report Updated: 28092018] Prices from USD $7221"

Quick Search

Relevant Topic

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...